1274 Infliximab for decompensated diabetes following immune checkpoint inhibitor therapy

• Mark Anderson,
• Adil Daud,
• Christine Kim,
• Zoe Quandt,
• Robert J Weber

Affiliations

Mark Anderson

1University of California San Francisco, San Francisco, CA, USA

Adil Daud

University of California San Francisco, San Francisco, CA, USA

Christine Kim

1From the Division of Endocrinology, Hypertension and Diabetes (S.M.G., S.H., N.S., C.K., E.W.S., G.H.W.), Brigham and Women`s Hospital, Boston, MA; NASA Center for Quantitative Cardiovascular Physiology, Modeling and Data Analysis (S.M.G., X.X., R.J.C.), Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA; and the Department of Cardio-Thoracic Surgery (S.M.G.), McGill University, Montreal, QC

Zoe Quandt

University of California San Francisco, San Francisco, CA, USA

Robert J Weber

University of California San Francisco, San Francisco, CA, USA